Novo Nordisk closes deal on technology platform

Novo Nordisk and SomaLogic have entered into a partnership which allows Novo Nordisk to use the technology platform Somascan in connection with the development of pharmaceutical drugs, while the Danish pharmaceutical company will deliver proteins for the platform.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

The collaborative agreement between Novo Nordisk and the global company SomaLogic means that the Danish pharmaceutical company can use the technology platform SomaScan for the development of treatments, for example (NASH), cardiovascular diseases and diabetes, according to a SomaLogic press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading